Single-Cell RNA Sequencing of PBMCs from Anti-PD-1-Treated Acral Melanoma Patients

54,793 high-quality single cells from peripheral blood mononuclear cells (PBMCs) of eight acral melanoma patients, sequenced by Qi Bao and published on figshare in March 2026. The data compares patients who developed immune-related adverse events (irAEs) on anti-PD-1 therapy, treated patients without irAEs, and untreated controls. Analysis revealed reconfiguration of the CD8+ T cell compartment, including expansion of cytotoxic cells and contraction of a transitional population.

Use Cases

• Identify immune cell signatures associated with adverse events based on single-cell transcriptional profiles.
• Analyze CD8+ T cell differentiation trajectories based on pseudotime analysis mentioned in the description.
• Evaluate the transitional-to-cytotoxic CD8+ T cell ratio as a potential biomarker for irAE risk.
• Investigate enrichment of cell-killing gene pathways in patients with immune-related adverse events.

Strengths

• Data is derived from 54,793 high-quality single cells, providing granularity at the cellular level.
• Includes a controlled comparison of three patient groups: those with irAEs, without irAEs, and untreated.
• Analysis is detailed in a peer-reviewed-style PDF, including methods and results for cellular composition and trajectory analysis.

Limitations

• Row count for the underlying data matrix is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred from the PDF description.
• The dataset is small in file size (402.4 KB), suggesting limited raw data scope.

Provenance

Source

Qi Bao via figshare.

Collection Method

Single-cell RNA sequencing (scRNA-seq) performed on PBMCs from eight acral melanoma patients.

Time Range

The temporal coverage of patient sample collection is not specified.

Freshness

Last updated 2026-03-18 07:44:52; freshness should be verified.

Geography

The geographic origin of the patient cohort is not specified.